Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis

Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA

(2022) Maria Mazzitelli et al.   Viruses-Basel

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV

(2021) Bernard Surial et al.   ANNALS OF INTERNAL MEDICINE

Weight gain before and after switch from TDF to TAF in a U.S. cohort study

(2021) Patrick WG Mallon et al.   Journal of the International AIDS Society

Management of Comorbidities in Treated HIV Infection: A Long Way to Go

(2021) Javier Martínez-Sanz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre

(2021) Juan Ambrosioni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV

(2021) Charlotte-Paige Rolle et al.   MEDICINE

Has COVID-19 changed the approach to HIV diagnosis?

(2021) Maria Mazzitelli et al.   MEDICINE

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

(2021) Hui-Min Chang et al.   Infection and Drug Resistance

The challenge of HIV treatment in an era of polypharmacy

(2020) David Back et al.   Journal of the International AIDS Society

Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV

(2020) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

The Impact of COVID-19 on HIV Treatment and Research: A Call to Action

(2020) Tiffany Chenneville et al.   International Journal of Environmental Research and Public Health

Evolution of drug Interactions with antiretroviral medication in people with HIV

(2020) Majdouline El Moussaoui et al.   Open Forum Infectious Diseases

Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls

(2019) D De Francesco et al.   HIV MEDICINE

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

(2019) Christian Hoffmann et al.   AIDS REVIEWS

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) Hans-Jürgen Stellbrink et al.   Lancet HIV

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

Interacciones de cobicistat y ritonavir en pacientes con VIH y sus consecuencias clínicas

(2019) Manuel Vélez-Díaz-Pallarés et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Contemporary Lifestyle Modification Interventions to Improve Metabolic Comorbidities in HIV

(2019) Kathleen V. Fitch   Current HIV/AIDS Reports

Weight gain and integrase inhibitors

(2019) Allison Ross Eckard et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study

(2018) Rafael Aguiar Maciel et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

(2018) Maureen Oliveira et al.   Retrovirology

The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality

(2018) Shejil Kumar et al.   Frontiers in Endocrinology

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study

(2017) Laurent Cotte et al.   PLoS One

The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future

(2015) Alice Tseng et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

(2014) Margaret T. May et al.   AIDS

Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up

(2014) Frederick J. Lee et al.   PLoS One

Multimorbidity in Older Adults

(2013) M. E. Salive   EPIDEMIOLOGIC REVIEWS

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes

(2012) Danijela Gnjidic et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY